undamentalytics Newsletter
Sign in

Bioage Labs, Inc. balance sheet

At the end of fiscal 2025, Bioage Labs, Inc. had total assets of $295m, total liabilities of $22.8m and shareholders' equity of $272m. It held $189m in cash against $2.6m of debt: net cash of $186m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents35418974
Receivables011
Total current assets357287330
Total assets358295397
Accounts payable236
Deferred revenue (current)864
Total current liabilities282019
Short-term debt630
Long-term debt30—
Total debt930
Total liabilities352322
Shareholders' equity323272375
Net debt (negative = net cash)−346−186−74
Shares outstanding—37m46m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BIOA vs RLAYBIOA vs CRBUBIOA vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bioage Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bioage Labs, Inc.